MAB8661
Anti-Influenza B Antibody, nucleoprotein, clones B2, B4 Blend
ascites fluid, Chemicon®, from mouse
Sign Into View Organizational & Contract Pricing
All Photos(1)
About This Item
UNSPSC Code:
12352203
eCl@ss:
32160702
NACRES:
NA.41
Recommended Products
biological source
mouse
Quality Level
antibody form
ascites fluid
antibody product type
primary antibodies
clone
B2, monoclonal
B4, monoclonal
species reactivity
human
manufacturer/tradename
Chemicon®
technique(s)
immunofluorescence: suitable
isotype
IgG
shipped in
wet ice
Specificity
Recognizes all subtypes of Influenza B. Blend of two clones that recognize the nucleoprotein antigen.
No cross-reactivity to influenza A, parainfluenza 1, 2 or 3, adenovirus or RSV.
No cross-reactivity to influenza A, parainfluenza 1, 2 or 3, adenovirus or RSV.
Immunogen
Influenza Blend.
Application
Anti-Influenza B Antibody, nucleoprotein, clones B2, B4 Blend detects level of Influenza B & has been published & validated for use in IF.
Indirect immunofluorescence at 1:100.
Final working dilutions must be determined by end user.
Final working dilutions must be determined by end user.
Research Category
Infectious Diseases
Infectious Diseases
Research Sub Category
Infectious Diseases - Viral
Infectious Diseases - Viral
Physical form
Ascites fluid with 0.1% sodium azide as a preservative.
Unpurified
Storage and Stability
Maintain for 1 year at -20°C from date of shipment. Aliquot to avoid repeated freezing and thawing. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap.
Analysis Note
Control
Influenza Control Slides, Catalogue Number 5010-5
Influenza Control Slides, Catalogue Number 5010-5
Other Notes
Concentration: Please refer to the Certificate of Analysis for the lot-specific concentration.
Legal Information
CHEMICON is a registered trademark of Merck KGaA, Darmstadt, Germany
Disclaimer
Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.
Not finding the right product?
Try our Product Selector Tool.
Storage Class
12 - Non Combustible Liquids
wgk_germany
nwg
flash_point_f
Not applicable
flash_point_c
Not applicable
Certificates of Analysis (COA)
Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Genetic variability of human metapneumovirus isolated from Chilean children, 2003-2004.
Carola Escobar,Vivian Luchsinger,Danielle Bruna de Oliveira,Edison Durigon et al.
Journal of Medical Virology null
Aaron G Schmidt et al.
Cell, 161(5), 1026-1034 (2015-05-12)
Vaccines for rapidly evolving pathogens will confer lasting immunity if they elicit antibodies recognizing conserved epitopes, such as a receptor-binding site (RBS). From characteristics of an influenza-virus RBS-directed antibody, we devised a signature motif to search for similar antibodies. We
Paulina Koszalka et al.
Antiviral research, 164, 91-96 (2019-02-17)
Baloxavir Marboxil (BXM) is an influenza polymerase inhibitor antiviral that binds to the endonuclease region in the PA subunit of influenza A and B viruses. To establish the baseline susceptibility of viruses circulating prior to licensure of BXM and to
Kevin R McCarthy et al.
Proceedings of the National Academy of Sciences of the United States of America, 118(23) (2021-06-03)
Immune memory of a first infection with influenza virus establishes a lasting imprint. Recall of that memory dominates the response to later infections or vaccinations by antigenically drifted strains. Early childhood immunization before infection may leave an imprint with different
Holly C Simmons et al.
PLoS biology, 21(12), e3002415-e3002415 (2023-12-21)
Antibody titers that inhibit the influenza virus hemagglutinin (HA) from engaging its receptor are the accepted correlate of protection from infection. Many potent antibodies with broad, intra-subtype specificity bind HA at the receptor binding site (RBS). One barrier to broad
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service